TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors: A Multi-Site Randomized Controlled Trial
Brief Summary: This study will implement and empirically evaluate the efficacy of a cognitive behavioral intervention program, titled, Post Admission Cognitive Therapy(PACT), for military service members and beneficiaries \[with Veterans expected to be added\] admitted for inpatient care due to severe suicide ideation and/or a recent suicide attempt.


Options:
A: Inclusion Criteria:

* Reason for Admission: Suicide-Related Event
* Baseline Completed within Preferably 48-72 Hours of Admission
* Over the Age of 18
* Provides Informed Consent

Exclusion Criteria:

* Medical Incapacity to Participate
* Serious Cognitive Impairment
* Expected Discharge within 72 Hours of Admission
B: Inclusion Criteria:

* Age between 12 and 18 years,
* Intellectual level over 70 (IQ\>70)
* For the experimental groups:

  * Patients with suicidal behavior:

    * Real attempt,
    * Interrupted attempt,
    * Aborted attempt or behaviors, or
    * Preparation actions (based on the Columbia Suicide Severity Rating Scale -C-SSRS criteria) present during the last 12 months and that persist in the actual moment.

Exclusion Criteria:

* Presence of Acute Psychosis,
* Eating Disorder with an BMI \< 18.5;
* Substance abuse in the current moment or during the last 6 months;
* Any neurological condition that curses with cognitive alterations; and
* Pregnancy.
C: Inclusion Criteria:

* Patient admitted to Massachusetts General Hospital inpatient psychiatric unit
* Age 18 and older
* Able to read/write in English
* SI documented on admission OR admission due to a suicide attempt
* Admission diagnosis of MDD (and current major depressive episode), confirmed using the Mini International Neuropsychiatric Interview (MINI) and inpatient chart review

Exclusion Criteria:

* Psychotic symptoms, as assessed using the MINI and inpatient chart review
* Cognitive disorder, assessed using a six-item cognitive screen developed for research
* Primary admission diagnosis of substance use disorder
D: Inclusion Criteria:

1. Has a valid health card issued by a Canadian province or Canadian student organization (ie: UHIP)
2. Has had at least 3 self-harm episodes (either suicidal or non-suicidal) in the past 5 years, including at least 1 in the past eight weeks
3. Is literate in English
4. Absence of 4 or more formal weeks of DBT in the past year (individual or group therapy components)
5. Indicates absence of knowledge of the DBT Skills
6. Is able to attend all sessions on scheduled study day

Exclusion Criteria:

1) Evidence of organic brain syndrome or mental retardation

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors: A Multi-Site Randomized Controlled Trial
Brief Summary: This study will implement and empirically evaluate the efficacy of a cognitive behavioral intervention program, titled, Post Admission Cognitive Therapy(PACT), for military service members and beneficiaries \[with Veterans expected to be added\] admitted for inpatient care due to severe suicide ideation and/or a recent suicide attempt.


Options:
A: Inclusion Criteria:

* ages 13-18
* English speaking adolescent and at least one English speaking parent
* receiving mental health treatment
* living with a parent or guardian willing to participate

Exclusion Criteria:

* Active Alcohol or Marijuana Dependence Diagnosis
* HIV infection
* Pregnant
* Current psychosis
* Cognitively unable to give assent
B: Inclusion Criteria:

* Reason for Admission: Suicide-Related Event
* Baseline Completed within Preferably 48-72 Hours of Admission
* Over the Age of 18
* Provides Informed Consent

Exclusion Criteria:

* Medical Incapacity to Participate
* Serious Cognitive Impairment
* Expected Discharge within 72 Hours of Admission
C: Inclusion Criteria:

* An episode of self harm within 48 hours before being admitted at the department;

  * age of 16 to 64 years;
  * Resident in the trial site catchments area,
  * Ability to complete a baseline assessment;
  * Ability to provide at least 2 verifiable contacts to improve tracking for subsequent assessments; and ability to understand and provide informed consent.

Exclusion Criteria:

* • A medical disorder that would prevent participation in an outpatient clinical trial.

  * Temporary resident unlikely to be available for follow up.
  * Diagnosis of Alcohol and other drug dependence, schizophrenia or Bipolar Disorders.
D: Inclusion Criteria:

* all patients will have had an episode of deliberate self harm
* test positive on either Drug Abuse Screening Test (DAST, Skinner 1982) or Alcohol Use Disorders Identification Test (AUDIT, Saunders 1983)

Exclusion Criteria:

* unable to give written informed consent
* unable to understand the purpose and nature of the research

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Nifedipine vs. Indomethacin in the Treatment of Preterm Labour and Short Cervix. A Randomized, Controlled Trial.
Brief Summary: The purpose of this study was to compare the effectiveness of nifedipine versus indomethacin as tocolytic for the treatment of preterm labour with short cervix (\< 2.5cms).


Options:
A: Inclusion Criteria:

1. Twin pregnancy
2. Gestational age between 24+0 and 32+6 weeks
3. Intact amniotic membranes
4. Threatened preterm labor
5. Age 18-50.

Exclusion Criteria:

1. Rupture of membranes
2. Vaginal bleeding resulting from placenta previa or placental abruption
3. Fever above 38°C
4. Severe preeclampsia
5. Maternal cardiovascular or liver diseases
6. Systolic blood pressure less than 90 mm Hg
7. Known uterine malformation
8. Intrauterine growth restriction below the fifth percentile
9. Non-reassuring fetal status
10. Antepartum diagnosis of major fetal malformations
11. Fetal death
12. Previous tocolytic therapy or Betamethasone treatment
B: Inclusion Criteria:

* English or Spanish speaking
* preterm premature rupture of membranes
* 26 - 32.6 weeks gestation
* cervical dilation \</= 4 cm

Exclusion Criteria:

* suspected intrauterine or intraamniotic infection
* \> 6 hours of tocolysis prior to admission
* positive fetal lung maturity
C: Inclusion Criteria:

* . Gestational age between 24-37weeks

  * Symptoms such as low backache , cramping ,pelvic pressure, excessive vaginal discharge and vaginal spotting .
  * Regular uterine contractions at least of 30 seconds duration at a rate of more than 4/30 minutes
  * Cervical changes dilatation less than 3cm,effacement lessthan50%.
  * Intact membranes.

Exclusion criteria

* Active vaginal bleeding and placental abruption.
* Chorioamnionitis and intrauterine infection
* Fetal conditions : fetal death or distress, lethal congenital or chromosomal abnormalities and intra uterine growth restriction
* Maternal conditions indicate that pregnancy shouldn't be continued: eclampsia , severe preeclampsia and cardiac diseases
* Drug specific contraindications(contraindication of tocolysis)
D: Inclusion Criteria:

* Pregnant women between 24 and 34 weeks of gestation.
* Cervical length (determined by transvaginal ultrasound) of 2.5 cms or less

Exclusion Criteria:

* All contraindications for tocolysis (fetal distress, abruptio placenta).
* Multiple pregnancy.
* All contraindications for the use of any of the two drugs (indomethacin or nifedipine).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Brief Summary: To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT


Options:
A: Inclusion Criteria:

Veterans will be considered eligible for study participation if the following criteria are met:

* 18 years of age (no maximum age is specified)
* working for pay 15 hours per week
* employed in the job for 6 months (to ensure that the Veteran has sufficient familiarity with the position and organization)
* current major depression and/or persistent depressive disorder symptoms based on DSM-5 criteria
* and current work limitations

Exclusion Criteria:

* Non-English speaking or reading
* bipolar disorder
* psychosis
* and/or planning to take maternity leave at any point in the next nine months
B: Inclusion Criteria:

* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria
* The current depressive episode must be equal to or greater than 8 weeks in duration
* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments

Exclusion Criteria:

* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder
* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder
C: Inclusion Criteria:

* diagnosed mild-moderate depression,
* 18 - 80 years,
* attending primary care center

Exclusion Criteria:

* schizophrenia,
* abuse/addiction,
* psychosis,
* bipolar syndrome,
* suicidal ideation or earlier suicide attempt,
* ongoing deep depression,
* generalized anxiety syndrome,
* not communicable in Swedish
D: Inclusion Criteria:

* Clinical diagnosis of major depressive disorder
* Must be able to swallow tablets
* Must be at least 18 years of age.

Exclusion Criteria:

* Clinical diagnosis of other psychiatric disorders
* Significant risk of suicide
* Unstable medical conditions.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Illness Management and Recovery (IMR) in Danish Community Mental Health Centres: Protocol of a Randomized, Assessor-blinded Multi-centre Clinical Trial of a Recovery-oriented Program for People with Schizophrenia or Bipolar Disorder
Brief Summary: The aim of this trial is to evaluate the effectiveness of the Illness Management and Recovery program for people diagnosed with schizophrenia or bipolar disorder in according to their level of functioning.


Options:
A: Inclusion Criteria:

* substance use
* acutely admitted to psychiatric hospital

Exclusion Criteria:

* dementia
* serious brain damage
* not speaking Norwegian or English
B: Inclusion Criteria:

* age 18 years or older
* meet DSM-IV criteria for cocaine abuse or dependence
* English speaking
* pass a brief quiz regarding study procedures to ensure understanding of the informed consent process.

Exclusion Criteria:

* dementia
* in recovery from pathological gambling
C: Inclusion Criteria:

* adults (age 18+)
* both sexes
* associated with one of the two participating community mental health centres
* diagnosed following the ICD-10 criteria of schizophrenia or bipolar disorder
* able to speak and understand Danish
* giving informed consent verbally and in writing

Exclusion Criteria:

* have a guardian or a forensic psychiatric arrangement
* comorbidity with the ICD-10 criteria of the diagnoses of dementia or mental retardation
* a large-scale substance abuse - if later on the abuse is under control inclusion in the trial will be possible
* a current home of supported housing - since the treatment as usual given to this group of patients is significant different from patients living independently
* a current involvement in a psycho-educational course - patients are eligible for participation in the trial after the psycho-educational course has ended if they meet the inclusion criteria at this point
* not given informed consent.
D: Inclusion Criteria:

* Enrolled patient at Community Psychiatric Clinic (CPC), a large mental health center in urban Seattle, Washington;
* Between 18 and 65 years of age;
* Diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse;
* CPC medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder
* Stimulant drug use one month before enrollment;
* Ability to understand written and spoken English;
* CPC clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study.

Exclusion Criteria:

* Any medical/psychiatric condition, or severity of that condition, that, in the opinion of Dr. Ries, the PI, would compromise safe study participation
* Chart defined organic brain disorder or dementia;
* Current participation in a methadone maintenance program;
* Any other circumstances that in the PI's opinion precludes safe study participation.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial
Brief Summary: Our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. As such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (HPA) on the prevalence of obesity.


Options:
A: Inclusion Criteria:

* Have received an annual physical
* Parent or guardian willing to give informed consent
* Parent or guardian willing to provide demographic and anthropometric data and agree to complete food intake and physical activity information for their child

Exclusion Criteria:

* Requires a specialized diet outside of that served by the Chicago Public Schools
* Has a chronic physical or behavioral disorder that requires participant to be under close medical psychological supervision and routinely absent from the study
B: Inclusion Criteria:

* Children from the selected grades and schools.
* Children who voluntarily accept participating in the program.
* Children whose parents must authorize their participation in the program, signing an informed consent document.

Exclusion Criteria:

• Participants with any incapacity to perform physical activity.
C: Inclusion Criteria:

* In the intervention group, all children of the selected classroom are exposed to the intervention.
* The data a will collected on all the children, but only the data from individuals (and their parents) who provided informed consent are included in the final analyses.
* Name, gender, date and place of birth are recorded at the start of the program, while weight, height, body mass index (BMI) and waist circumference variables (identified set of anthropometric measures) are recorded in each of the 3 academic years of the study.

Exclusion Criteria:

* No adequate age
* Lack of inclusion criteria
D: Inclusion Criteria

* aged 12-14 years
* enrolled in participating school

Exclusion Criteria

* Unable to give informed consent
* Presence of an underlying medical conditions
* Already enrolled in a physical activity intervention

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial
Brief Summary: Our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. As such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (HPA) on the prevalence of obesity.


Options:
A: Inclusion Criteria:

* In the intervention group, all children of the selected classroom are exposed to the intervention.
* The data a will collected on all the children, but only the data from individuals (and their parents) who provided informed consent are included in the final analyses.
* Name, gender, date and place of birth are recorded at the start of the program, while weight, height, body mass index (BMI) and waist circumference variables (identified set of anthropometric measures) are recorded in each of the 3 academic years of the study.

Exclusion Criteria:

* No adequate age
* Lack of inclusion criteria
B: Inclusion Criteria:

* Female children of age 9-11 yrs who are enrolled in the public sector school with a compound facility would be included in the study. Intervention would be offered to those only who will have normal age specific weight in percentiles.

Exclusion Criteria:

* Those who are suffering from any chronic illness due to they which cannot participate and those who are mentally or physically disabled will be excluded from the study.
C: Inclusion Criteria:

* second- or third-grade pupils
* affiliation with the French Health Care System
* written informed consent

Exclusion Criteria: no inclusion criteria were based on pathological, ethnical or socio-educative indicators
D: Inclusion Criteria:

Children:

* 5-7 year-old female or male of Hispanic origin (identified by parent)
* resident of Davidson County or adjacent counties
* ≥25th percentile of age- and sex-specific BMI (CDC growth charts) or one parent/caregiver with BMI ≥ 25 kg/m2
* More than one child may enroll per family

Parents:

* Hispanic origin (self-identified)
* Spanish speaker
* adult age 18 or older
* parent of at least one eligible child
* Only one parent per family may enroll as a study participant and respond to questionnaires

Exclusion Criteria:

Children:

* BMI ≥ 35 kg/m2
* Medical conditions affecting growth
* Conditions limiting participation in the interventions or measurements
* Taking medications affecting growth
* No consent or inability to understand informed consent
* Incomplete or missed baseline assessments
* Plan to move from geographic area within the next 12 months.

Parents:

* No exclusions

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis
Brief Summary: This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.


Options:
A: Inclusion Criteria:

* Clinical diagnosis of Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis
* Patients with active disease refractory to traditional disease modifying drugs (methotrexate, leflunomide, sulphasalazine, cyclosporine, hydrossiclorochine)
* Patients eligible to begin conventional biologic therapy

Exclusion Criteria:

* Any criteria excluding treatment with biologic drugs according to international guidelines
B: Inclusion Criteria:

* Have a diagnosis of RA for at least 3 months prior to screening
* Have no history of latent or active tuberculosis (TB) and test negative for TB

Exclusion Criteria:

* Have inflammatory diseases other than RA
* Have been treated with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than methotrexate (MTX), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent
* Have received intramuscular (IM), IV, or intra-articular corticosteroids within 4 weeks of study agent administration
* Have a known hypersensitivity to human Ig proteins
* Have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent
* Have received alefacept, efalizumab, natalizumab, rituximab, or any B-cell-depleting agent
* Have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent
* Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis, prior to screening
* Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening
* Have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)
C: Inclusion:

- Generally healthy of at least 18 years of age with active rheumatoid arthritis.

Exclusion:

- A history or presence of clinically important medical disease.
D: Inclusion Criteria:

* patients at least 18 years of age with moderate to severe active RA for at least 6 months;
* inadequate response to current anti-rheumatic therapies, including 1 or more traditional DMARDs;
* stable DMARD therapy for at least 8 weeks before entering study;
* patients of reproductive potential must be using reliable methods of contraception.

Exclusion Criteria:

* major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study;
* patients who have previously failed treatment with an anti-tumor necrosis factor agent;
* women who are pregnant or breast-feeding.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Inclusion Criteria:

* age ≥ 18 years
* smoked tobacco during the prior 30 days
* have an active phone number
* provide consent in English, Spanish or Mandarin

Exclusion Criteria:

* Patients will be excluded if they use only smokeless tobacco or products such as betel (since there is not yet efficacy data for treating use of these tobacco products in the inpatient setting)
* are pregnant or breastfeeding
* are discharged to an institution (e.g. jail/prison, nursing home, long-term psychiatric facility).
B: Inclusion Criteria:

* Current use of tobacco
* Age 18 or older
* Visit with a clinician that day
* Patient at one of the 16 practices in the study

Exclusion Criteria:

* Unable to participate in a self-administered exit survey
C: Inclusion Criteria:

* Current smoker (i.e., any tobacco use in past 30 days)
* Seen in VA Mental Health Clinic in prior 12 months

Exclusion Criteria:

* Dementia
* Does not speak English
* Does not have a telephone and mailing address (necessary to mail out consent materials and to deliver the telephone-based intervention)
D: Inclusion Criteria:

* Enrolled in Medicaid or uninsured, 18 years or older, able to read and speak English, provided verbal consent to be contacted by quit line to follow-up, sought quit line services for being primarily a smoker

Exclusion Criteria:

* Primary use of other forms of tobacco such as smokeless tobacco, not understanding English

Answer: A